Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Lockshin

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
JCI Insight|October 26, 2020
Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over timeAparna Sajja, Khaled M Abdelrahman, Aarthi S Reddy, et al.
Journal of the American Academy of Dermatology|November 4, 2019
Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort studyEric Munger, Harry Choi, Amit K Dey, et al.
Lancet (London, England)|September 18, 2022
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trialAmy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
JCI Insight|October 26, 2020
Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over timeAparna Sajja, Khaled M Abdelrahman, Aarthi S Reddy, et al.
Journal of the American Academy of Dermatology|November 4, 2019
Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort studyEric Munger, Harry Choi, Amit K Dey, et al.
Lancet (London, England)|September 18, 2022
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trialAmy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
Pageof 3